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Role of Programmed Cell Death in
Carcinogenesis
by John T. Isaacs
Cells possess within their repertoire of genetic programs the ability not only to proliferate
and be functionally active, but also to activate and undergo a process of self-induced destruc-
tion. This process, called programmed cell death, involves a genetic reprogramming ofthe cell
that results in an energy-dependent cascade ofbiochemical and morphological changes within
the cell that result in its death and elimination. Activation ofthis programmed death process is
controlled by a series of endogenous cell-type-specific signals. In addition, a variety of exoge-
nous cell-damaging treatments (e.g., radiation, chemicals, and viruses) can activate this path-
way if sufficient injury to the cell occurs. Because a cell must undergo a series of molecular
changes to acquire the malignant phenotype and because these changes are often induced by
agents or treatment that damage the cell over an extended period of time, anything that
enhances the survival of initiated/damaged cells will promote the carcinogenic process. This
paper presents an overview of the regulation and mechanism of programmed cell death and
how derangement ofthis regulation may be involved in carcinogenesis.
Introduction
Major progress has been made in identifying the fac-
tors that regulate the rate of cell proliferation (e.g.,
Rb, p53, cyclins/cdc kinase). Studies have demonstrat-
ed that the proliferative cell cycle has a series of regu-
latory check points (1,2). These check points must be
traversed before the cell can progress from to Go to
mitosis (1,2). Until recently, it was assumed that the
factors that regulate the entrance and progression
through the proliferative cell cycle exclusively control
cell number. This assumption is incorrect because the
number of cells in a tissue, whether normal or malig-
nant, depends on the qualitative relationship between
the rate of cell proliferation and cell death. In normal
adult tissues, these rates are balanced such that a
steady state (i.e., self-renewing) relationship is main-
tained in which the number of cells in the tissue nor-
mally does not increase continuously with time. This
steady state is regulated by a series of both systemic
hormones and local growth factors that regulate both
the rate ofcell proliferation and cell death (3). A funda-
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mental characteristic ofcancer is that, unlike their nor-
mal counterparts, the cancer cells' rate ofproliferation
exceeds the rate of death, thus resulting in continuous
net growth of cancer. Thus, malignant conversion
results in a dysfunction in the regulation of cell prolif-
eration and/or cell death. Regulation of cell prolifera-
tion in carcinogenesis is not the focus of this paper.
Instead, the regulation and mechanism of cell death
and the involvement ofchanges in cell death regulation
in carcinogenesis is discussed.
Regulation and Mechanisms of
Cell Death
Cell death can involve processes equal in complexity
and regulation to those involved in cell proliferation.
This has been appreciated for many years by develop-
mental biologists. It is this group of scientists who
coined the term "programmed cell death" to distin-
guish the active, orderly, and cell-type-specific death
observed in developing organisms from necrotic cell
death. Necrotic death is a response to pathological
changes initiated outside ofthe cell and can be elicited
by any of a large series of non-specific factors that
result in a change in the plasma membrane permeabili-
ty. This increased plasma membrane permeability
results in cellular edema and the eventual osmotic lysis
ofthe cell. In necrotic cell death, the cell has a passive
role in initiating the process of cell death (i.e., the cell
is killed by its hostile microenvironment). Program-J. T. ISAACS
med cell death is a process whereby a cell is activated
by various signals to undergo an energy-dependent
process of self-induced death. In this self-induced
death, the cell is an active participant in its own
demise [i.e., the cell is induced to commit "suicide" by
specific signals in an otherwise normal microenviron-
ment (4,5)]. Programmed cell death is a widespread
phenomenon occurring normally at different stages of
morphogenesis, growth, and development of meta-
zoans (6). It also occurs in adult tissue (6). Programmed
cell death is initiated in specific cell types by tissue-
specific extracellular agents, generally hormones or
locally diffusing chemicals. Programmed cell death can
be activated either by the presence of a tissue-specific
inducer [e.g., glucocorticoid induces death ofsmall thy-
mocytes (7)] or by the lack of a tissue-specific repres-
sor [e.g., decrease in serum adrenocorticotropin hor-
mone results in cell death in the zona reticularis ofthe
adrenal (8)]. Once initiated, either by the presence of
an inducer or by lack of a repressor, programmed cell
death leads to a cascade ofbiochemical and morpholog-
ical events that results in the irreversible degradation
of the genomic DNA and fragmentation of the cell
(7,9-12). The morphological pathway for programmed
cell death is rather stereotypic and has been termed
"apoptosis" to distinguish this process from necrotic
cell death.
Apoptosis was originally defined by Kerr et al. (4) as
the orderly and characteristic sequence of structural
changes resulting in the programmed death ofthe cell.
The temporal sequences of events of apoptosis com-
prise chromatin aggregation, nuclear and cytoplasmic
condensation, and eventual fragmentation ofthe dying
cell into a cluster ofmembrane-bound segments (apop-
totic bodies) which often contain morphologically intact
organelles. For example, in apoptosis (as opposed to
necrotic death), mitochondria do not swell and lose
their function as an early event in the process. Instead,
functionally active mitochondria are often contained in
apoptotic bodies. These apoptotic bodies are rapidly
recognized, phagocytized, and digested by either
macrophages or adjacent epithelia cells. In pro-
grammed cell death, fragmentation ofgenomic DNA is
an irreversible event that commits the cell to die and
occurs before changes in plasma and internal mem-
brane permeability (5). In many systems, DNA frag-
mentation has been shown to result from activation of
an endonuclease present within the cell's nucleus,
which selectively hydrolyzes DNA at sites between
nucleosomal units, thus resulting in the stereotypic
nucleosomal-sized ladder of DNA fragments (7,9-12).
In many cell types nuclease is calcium dependent, and
its activation is triggered by a sustained elevation in
the intracellular free Ca2+concentration initiated early
in programmed cell death (13-18). DNA is also degrad-
ed during necrotic cell death; however, this is a late
event in necrotic cells whose plasma and internal mem-
branes have already lysed. In necrotic death, DNA is
degraded into a continuous spectrum of sizes as a
FIGURE 1. Schematic view ofthe cell cycle options forGocell.
result ofthe simultaneous action oflysosomal proteas-
es and nucleases released in dead cells (19).
Thus, the period ofDNA fragmentation (the F phase)
can be used to divide the temporal series of events
involved in programmed cell death, much as the period
of DNA synthesis (the S phase) is used to divide the
proliferative cell cycle. The overall cell cycle control-
ling cell number is thus composed of a multi-compart-
ment system in which the cell has at least three possi-
ble options (Fig. 1). The cell can be a) metabolically
active but not undergoing either proliferation or death
(i.e., Go cell), b) undergoing cell proliferation (i.e., Go to
mitosis), or c) undergoing cell death by either the pro-
grammed pathway (i.e., Go0-D1,-F->D2 apoptotic cel-
lular fragmentation) or the nonprogrammed (i.e.,
necrotic) pathway. The systemic and local growth fac-
tor signals that regulate the progression within this
cell cycle are cell type specific and are uniquely deter-
mined as part of the differentiated phenotype of the
particular cell. Thus, the same growth factor (e.g.,
TGFP1) can have either agonistic or antagonistic
effects within the cell cycle for different cell types
(e.g., mesenchymal versus epithelial cells). Therefore,
the specific details of the regulatory pathway for the
cell cycle vary between different cell types.
Cell Cycle for Prostatic Glandular
Cells
The cell cycle ofprostatic glandular cells will be used
as an example ofhow the number ofa specific cell type
is physiologically regulated within the body. Androgen
is the major systemic hormone forthe prostate (3). The
major source of androgen in the body is the testis,
which synthesizes and secretes testosterone (the
major physiological androgen) into the blood. The
hypothalamic-pituitary-testis axis is tightly regulated
so that the blood level of testosterone is maintained
within a defined physiological range. Testosterone,
derived from the blood, enters into prostatic cells
where the 5a-reductase enzyme converts it into 5a-
dihydrotestosterone [DHT (20)]. Due to the efficiency
of this prostatic 5a-reductase activity, the DHT con-
centration within the prostate is 4- to 5-fold higher
than testosterone, and 95% of the androgenic steroid
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present within prostatic cell nuclei is DHT (21). In
addition, the affinity ofthe androgen receptor is higher
for DHT than for other endogenously occurring
steroids (23). DHT is thus the major intracellular effec-
tor ofandrogen action within the prostate (24).
In the normal adult prostate, the epithelial cells are
continuously turning over with time. In this self-
renewing condition, the rate of prostatic cell death is
balanced by an equal rate ofprostatic cell proliferation
such that neither involution or overgrowth ofthe gland
normally occurs with time. If an adult male is castrat-
ed, the serum testosterone level rapidly decreases to
below a critical value (19). As a result, the prostate
rapidly involutes. This involution is due to a major loss
in the epithelial, not the stromal, compartment of the
prostate (25). The chronic requirement for androgen
by the epithelial compartment is due to the fact that
androgens regulate the total prostatic epithelial cell
number by affecting both the rate ofglandular cell pro-
liferation and the rate of glandular cell death.
Androgen does this by chronically stimulating the rate
of cell proliferation (i.e., agonistic ability of androgen)
while simultaneously inhibiting the rate of cell death
(i.e., antagonistic ability of androgen) of the prostatic
glandular epithelium (26).
The agonistic ability ofandrogen to stimulate prosta-
tic glandular cell proliferation in vivo is well estab-
lished. For example, ifan animal or human is castrated
and the prostate is allowed to involute and then the
host is given sufficient exogenous androgen replace-
ment, the prostatic glandular epithelial cells are
recruited out of Go and into the proliferative cell cycle
(27,28). Associated with this recruitment into the pro-
liferative cell cycle is the enhanced expression of a
series of genes including c-fos, c-H-ras, c-Ki-ras, c-
myc, and b-FGF (29). This recruitment results in a
proliferative response that restores the prostatic glan-
dular epithelial cell number (30). Although the agonis-
tic ability ofandrogen on prostatic glandular cell prolif-
eration has been well established by a variety of
studies, the additional ability ofandrogen to antagonis-
tically inhibit the rate of death ofthese glandular cells
has been fully appreciated only recently (26,31).
The importance of the androgenic regulation of pro-
static glandular cell death is illustrated by the follow-
ing observations. In the adult male rat, only 2% of the
total prostatic cells die per day when the serum testos-
terone level is sufficient for the chronic steady-state
maintenance ofthe gland; that is, the cell proliferation
rate per day is also 2% to balance this normal rate of
cell death (26). Within 2 hr after castration of an adult
male rat, serum testosterone decreases to below 2% of
the value present in the intact host (19). This rapid
decline in serum testosterone results in the prostatic
DHT concentration decreasing within the first 24 hr
after castration to below a critical threshold value,
triggering a cascade of events in the androgen-depen-
dent prostatic glandular epithelial cells that eventually
results in their death (19,25,32-34).
This pathway is activated when the extracellular
level of various androgen-regulated peptide growth
factors (e.g. b-fibroblast growth factor, keratinocyte
growth factor, insulinlike growth factor-I, epidermal
growth factor) decreases after castration to below a
critical level within the prostate (28). The time
required for the critical decrease in these growth fac-
tor levels varies regionally within the prostatic glandu-
lar cell population. The extracellular levels near some
epithelial cells reach the critical value within 2 days
after castration, whereas these values are not reached
near other cells until 10-14 days after castration. Once
this critical decrease occurs, however, a major genetic
reprogramming occurs in the prostatic glandular cells,
resulting in the activation phase (i.e., DI) of the death
cycle (Fig. 1).
During the DI phase, certain genes that were active-
ly transcribed and translated before castration (e.g.,
genes for secretory proteins, polyamine synthesis
enzymes, and endoplasmic reticular proteins) are
rapidly turned off, while other genes which initially
were not actively transcribed and translated are now
rapidly induced when the program for cell death is
activated. Some of the genes that are enhanced during
the DI phase of the death cycle are c-myc (35), c-fos
(35), heat shock 70 (35), calmodulin (unpublished obser-
vations), glutathione s-transferase Yb1 (3A), a-prothy-
mosin (unpublished observations), sulfated glycopro-
tein-2 (37), transforming growth factor 1 and P:j (34),
tissue transglutaminase (unpublished observations),
and mitochondrial cytochrome C-oxidase subunit I
(unpublished observations). The result of this genetic
reprogramming is that during the DI portion of the
death cycle (Fig. 1), the total level of mRNA synthesis
decreases, cell proliferation stops, endoplasmic reticu-
lar volume and complexity decreases (i.e., cellular atro-
phy), polyamine level decreases, and intracellular free
Ca2+ levels increase. These changes are reversible ifsuf-
ficient androgen is restored.
Once the intracellular Ca2+ reaches a critical level,
endonuclease in the cell nucleus is activated (33,38).
The decrease in nuclear polyamine levels, coupled with
a rise in the nuclear level ofthe highly acidic (pl = 3.5)
x-prothymosin protein induces a change in the genom-
ic DNA, opening up the linker region between nucleo-
somes. This enhances the accessibility of the DNA to
the Ca2+Mg2+-dependent endonuclease. Once this occurs,
DNA fragmentation begins (i.e., F portion ofthe death
cycle; Fig. 1) and cell death is no longer reversible.
DNA fragmentation continues until all of the genomic
DNA is degraded into nucleosomal-size pieces (19).
During this F stage, the nuclear morphology changes
(e.g., chromatin condensation with nuclear margina-
tion), even though the plasma and lysosomal mem-
branes are still intact and mitochondria are still func-
tional. During the subsequent D2 portion of the death
cycle, Ca2+-dependent tissue transglutaminase actively
crosslinks various membrane proteins, and cell surface
blebbing, nuclear disintegration, and eventually cellu-
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lar fragmentation occur, resulting in clusters of mem-
brane-bound apoptotic bodies. Once formed, these
apoptotic bodies are rapidly phagocytized by macro-
phages or neighboring epithelial cells. The half-life of
apoptotic bodies in the prostate induced after castra-
tionis 4-6hrs (unpublished observations). Onceingested,
the apoptotic bodies are degraded within the lysosome
ofthe phagocytizing cells into reusable macromolecules
(e.g., amino acids, nucleotides, carbohydrates).
Programmed cell death induced by androgen abla-
tion does not require the prostate cells to undergo cell
proliferation. This is demonstrated by the fact that
there is no increase in the percentage ofprostate cells
in the S phase of the cell cycle as determined at 6 hr
intervals, between 0 and 72 hr after castration, using
flow cytometric methods (Berges et al., unpublished
results). In contrast, the already low percentage of
prostatic cells in the S phase actually decreases after
castration during the period when cells are rapidly
dying. This has been confirmed by pulse-chase experi-
ments in which animals were injected with [3H]thymi-
dine 24 hr after castration and the prostates examined
over the subsequent 24 hr by radioautography to
determine the percentage of apoptotic bodies that are
[3H]thymidine labeled. These results demonstrated
that at all times during the chase period, less than 10%
of the apoptotic bodies are thymidine labeled, and the
vast majority (>90%) of the prostatic cells that die
after castration do so without entering the S phase of
the cell cycle (i.e., the cells die in interphase).
Programmed Cell Death Induced by
Damaging Agents
Programmed death of prostatic glandular cells after
androgen ablation is an extreme case of physiological
elimination of a group of cells. Normally in the adult,
androgen levels are regulated such that such cata-
strophic elimination ofprostatic cells does not occur. A
low level (-2% per day) ofthe prostatic glandular cells
do undergo programmed cell death even in the pres-
ence of adequate androgen (26). Presumably, this is
due to the accumulation ofa critical amount ofdamage
to the cells secondary to their secretory function.
These glandular cells produce and secrete large
amounts of protease and polyamines (39), both of
which can damage cells. As discussed below, if a criti-
cal amount of such endogenously generated damage is
accumulated, the programmed cell death pathway is
activated. This has been demonstrated by a variety of
pathological conditions, including physical [e.g.,
radiation, physical trauma, cold shock, chemicals, and
infectious agents (e.g., viruses)]. For example, when
exposed for 1-2 hrs to cold, but not freezing tempera-
tures, nondividing cells undergo programmed cell
death when rewarmed to 37°C (40). With respect to
ionizing radiation-induced damage, lymphocytes are
the most sensitive cell in the body. Resting, nonprolif-
erating lymphocytes rapidly undergo programmed cell
FIGURE 2. Schematic view ofthe cell cycle options for a cell in either
Go orin the proliferative cell cycle.
death after appropriate doses ofionizing radiation (41).
Viral infection can also induce programmed cell death
in various host target cells (41-43). These results sug-
gest that normal cells activate their programmed cell
death pathway when they have accumulated a critical
amount ofinjury that cannot be adequately repaired.
Previous studies have demonstrated that when the
DNA of a proliferating cell is sufficiently damaged
with a variety of chemicals (e.g., alkylating agents,
mitogenic agents, etc.), the cell arrests in G2 and
undergoes programmed cell death (44). Likewise,
agents (e.g., 5-flurodeoxyuridine) that inhibit the pro-
gression through the S-phase of the proliferative cell
cycle induce programmed cell death (45). Mimosine,
which arrests cells in the G1 phase of the proliferative
cell cycle (46), can also induce programmed cell death
(unpublished observations). The mechanism for how
the cell senses such cellular arrest during the prolifera-
tive cell cycle and activates programmed cell death is
not understood. One explanation ofthe cytotoxic effect
of cell cycle arrest is that these agents dissociate the
normally integrated cell cycle events, which leads to
"unbalanced growth" and eventually programmed
death of the cells (47). Regardless of the mechanism,
these results clearly demonstrate that programmed
cell death can be activated not only in cells in Go but
also in cells in the various parts ofthe proliferative cell
cycle (Fig. 2).
Programmed Cell Death and
Carcinogenesis
The fact that potentially mutagenic/carcinogenic
damage to a cell can activate its self-induced elimina-
tion via programmed death has direct implications for
both the normal rate oftissue renewal and carcinogen-
esis. In 1982, Umansky (48) proposed that pro-
grammed cell death is critically involved in the process
ofcarcinogenesis. Umansky reasoned that the frequen-
cy of mutation (i.e., 104-10-9 per gene per cell genera-
tion) multiplied by the daily number ofcells dividing in
a human (i.e., 109 cell/day) should produce a large num-
ber of cells with a potential oncogene mutation (48).
This would predict that tumor occurrence should be
very high. To explain why a tumor does not always
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develop in an individual, Umansky suggested that
induction of programmed cell death was at least one
mechanism for the elimination of cells with oncogenic
mutations (48). This suggestion is based on the obser-
vation that most carcinogens are damaging and thus
also cytotoxic, as well as transforming. Thus, the
majority of cells that become initiated by carcinogens
undergo programmed cell death before giving rise to
progeny. Due to their death, these initiated cells are
eliminated from the tissue population without increas-
ing the risk of tumor formation. Umansky proposed in
order for the cell to be transformed and give rise to a
tumor, it must undergo changes that modify its
responsiveness to programmed cell death so as not to
be initially eliminated after exposure to the carcinogen
(48).
Modulation of Responsiveness to
Programmed Cell Death
Any mechanism that allows more carcinogen-injured
cells to survive will increase the risk of developing a
cancer. Also because multiple genetic changes are
required for a cell to become tumorigenic, any mecha-
nism that enhances cell survival increases the likeli-
hood of accumulating the necessary genetic changes
required for the development of a tumorigenic pheno-
type. In this regard it is highly significant that the Bcl-
2 oncogene has been demonstrated to be oncogenic not
due to an effect on cell proliferation but due to an
effect on cell survival (49,50). Overexpression of the
Bcl-2 protein occurs in human follicular B-cell lym-
phomas associated with a t(14;18) chromosomal trans-
location. Overexpression of the Bcl-2 protein extends
the normal survival of B-cells by inhibiting pro-
grammed cell death and thus increasing the risk of
acquisition of additional genetic changes needed for
tumor progression (49). Additional studies have
demonstrated that Epstein-Barr virus infection can
likewise inhibit programmed cell death of human B-
lymphocytes and that this is due to the upregulation of
Bcl-2 expression in these virus-infected cells (51,52).
The adenovirus ElA and E1B proteins are required
for oncogenic transformation of primary rodent cells.
The ElA proteins alone are sufficient for induction of
DNA synthesis and cellular immortalization. Complete
high-efficiency transformation, however, requires both
ElA and E1B gene expression (53). The E1B gene
encodes two distance transforming proteins of 19,000
and 55,000 kDa. When expressed in the absence ofthe
19 kDa E1B protein, ElA proteins are acutely cytotox-
ic via induction of programmed cell death (44,54,55).
ElA alone can efficiently initiate the formation of foci
which subsequently undergo abortive transformation
in which stimulation of cell proliferation is counteract-
ed by cell death. Cell lines with an immortalized
growth potential eventually arise with low frequency.
Coexpression of the ElB 19 kDa protein with ElA is
sufficient to overcome abortive retransformation to
produce high-frequency transformation (53). These lat-
ter results demonstrate that if the rate of cell death is
too high, enhancement of cell proliferation is not
always sufficient for full transformation.
Similar observations have been made in studies of
experimental liver carcinogenesis. Using cellular
markers, it has been demonstrated that when rats are
exposed to initiative doses ofN-nitrosomorpholine, the
rate of cell proliferation is much higher in preneoplas-
tic liver foci than in the normal liver (56). Despite this
enhanced proliferation, no net growth ofthe foci occurs
and no liver tumors develop because the enhanced pro-
liferation is counterbalanced by an equally increased
rate of programmed cell death in these foci (56).
During tumor promotion induced by phenobarbital
(PB) treatment, a rapid net expansion of the altered
foci occurs without an increase in cell proliferation.
This effect is due to the PB treatment inducing a
decrease in the rate of programmed cell death such
that this rate is now lower than the rate of cell prolif-
eration, thus allowing net growth of the foci into the
continuously growing liver cancer.
These studies demonstrate that treatments that
decrease the rate of cell death enhance the carcino-
genic process. Along this line, it is significant that the
state of a cell at the time it receives a potential signal
to undergo programmed cell death can alter this death
response. Studies have demonstrated that pro-
grammed cell death can be induced in a variety of cell
types after removal of critical trophic factors and that
this death response can be enhanced or inhibited
depending on the status ofthe protein kinase C activi-
ty ofthe cell. For example, activation ofprotein kinase
C with phorbol esters inhibited the programmed death
of murine interleukin-2 (IL-2) dependent T-cells or
murine splenic mitogen-stimulated blast cells induced
by IL-2 deprivation (57). Similarly, the programmed
cell death ofmurine embryo cells induced after epider-
mal growth factor deprivation is inhibited if protein
kinase C is activated by phorbol esters (58). Also, the
programmed death ofhuman umbilical vein endothelia
cells induced by serum deprivation was inhibited by
phorbol ester treatment. Treatment ofthese cells with
protein kinase C inhibitors induced programmed death
even if the cells were maintained in the presence of
appropriate growth factors (59). In contrast, the pro-
grammed cell death of murine thymocytes induced by
glucocorticoid exposure is inhibited ifprotein kinase C
activity is inhibited (60). These results demonstrate
that depending on the cell type, the state of activation
of protein kinase C can modify the induction of pro-
grammed cell death.
The modifying effects ofprotein kinase C upon cold-
shock-induced programmed cell death has also been
reported. When non-growing (i.e., stationary phase)
hamster fibroblast cells are exposed for 1-2 hr at cold
but not freezing temperatures and then rewarmed at
37°C, the cells undergo programmed cell death. In con-
trast, when exponentially growing hamster fibroblasts
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are exposed to the cold and rewarmed, they do not
undergo programmed cell death (40). A similar differ-
ential response to cold shock is observed between
growing and stationary-phase human synovial cells
(61). If protein kinase C is inhibited in these growing
synovial cells, these cells now become sensitive to cold
shock-induced programmed cell death. Likewise, if
protein kinase C is activated by phorbol ester in sta-
tionary-phase synovial cells, these cells become resis-
tant to cold shock-induced programmed cell death (61).
Conclusion
The results presented demonstrate that the state of
the cell at the time ofa potential signal to undergo pro-
grammed cell death can modify and even prevent this
process. Such modification has obvious ramifications
for carcinogenesis. For example, exposure to an appro-
priate dose of carcinogen can result in no cells being
initiated in one type of tissue, but this same dose can
be quite carcinogenic in cells of another organ in the
same host. One explanation for this paradoxical situa-
tion could be that intransformation-resistant cells, car-
cinogen exposure activates programmed cell death,
thus eliminating any initiated cells, whereas in trans-
formation-sensitive cells, the state ofthese cells allows
an occasional initiated cell to modify and thus prevent
reactivation of its programmed death pathway. This
would result in the survival ofthe initiated cell, allow-
ingit to grow and give rise to atumor. Such apossibili-
ty could explain the tissue specificity ofparticular car-
cinogenic treatments even though these treatments
are damaging to all cell types exposed. In addition,
such a possibility could explain how certain types of
promoters function. Certain types of promoters (e.g.,
phenobarbital for liver cancers, phorbol esters for skin
cancers, viral infection for certain lymphomas) could
modify the response of initiated cells so that they do
not complete the programmed cell death pathway. In
this manner, initiated cells could survive long enough
so that their progeny undergo all the genetic changes
needed to acquire a tumorigenic phenotype. Major
unanswered questions are how cells sense damage and
activate this programmed cell death pathway and how
various agents modify this sensing mechanism so that
injured cells are not eliminated. These will be fruitful
areas of research with regard to the role of pro-
grammed cell death in both the initiation and promo-
tion stages ofcarcinogenesis.
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